Camlin Fine Sciences Share Price

NSE
CAMLINFINE •
BUY

1W Return

1M Return

6M Return

1Y Return

3Y Return

The current prices are delayed, login or Open Demat Account for live prices.
Start SIP in Camlin Fine Sciences
Camlin Fine Sciences Stock Performance
52 Week Low - High
Today’s Low - High

Open

Prev. Close

Total Traded Value

View details of Market Depth
Camlin Fine Sciences Fundamental

Market Cap (in crs)

Face Value

Turnover (in lacs)

Key Metrics
Qtr Change %
108.29% Gain from 52W Low
34.5
Dividend yield 1yr %
0

Camlin Fine Sciences Key Financials

View more

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

Camlin Fine Sciences Quarterly Revenue

Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
433.49 Cr
422.97 Cr
395.85 Cr
401.69 Cr
385.89 Cr

Camlin Fine Sciences Yearly Revenue

Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019
1628.62 Cr
1687.36 Cr
1445.12 Cr
1192.09 Cr
1052.58 Cr
905.95 Cr

Camlin Fine Sciences Quarterly Net Profit/Loss

Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
-5.62 Cr
-116.61 Cr
-34.65 Cr
-81.79 Cr
-14.28 Cr

Camlin Fine Sciences Yearly Net Profit/Loss

Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019
-104.88 Cr
39.81 Cr
60.51 Cr
65.36 Cr
29.83 Cr
3.06 Cr
Camlin Fine Sciences Result Highlights
  • Camlin Fine Sciences Ltd reported a 0.1% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 12.2%.

  • Its expenses for the quarter were up by 1.5% QoQ and 9.1% YoY.

  • The net profit decreased 93.6% QoQ and decreased 47.6% YoY.

  • The earnings per share (EPS) of Camlin Fine Sciences Ltd declined at 0.2 during Q3FY25.

    Read more

Data Source: BSE, Company announcements

The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

Camlin Fine Sciences shareholding Pattern

Promoter
49.1%
Foreign Institutions
1.5%
Mutual Funds
3.5%
Domestic Institutions
3.8%
Public
45.6%
Promoter
48%
Foreign Institutions
0.8%
Mutual Funds
3.4%
Domestic Institutions
3.3%
Public
47.8%
Promoter
48%
Foreign Institutions
0.8%
Mutual Funds
4.2%
Domestic Institutions
4.2%
Public
46.9%
Promoter
48%
Foreign Institutions
1%
Mutual Funds
4.4%
Domestic Institutions
4.9%
Public
46.1%
Promoter
48%
Foreign Institutions
1.7%
Mutual Funds
2.8%
Domestic Institutions
4.5%
Public
45.7%
Promoter
48%
Foreign Institutions
1%
Mutual Funds
2.8%
Domestic Institutions
3.7%
Public
47.2%

Camlin Fine Sciences Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
Current Price
Bullish Moving Averages
8
Bearish Moving Averages
8
5Day EMA
165.30
10Day EMA
164.90
12Day EMA
164.60
20Day EMA
163.70
26Day EMA
162.80
50Day EMA
157.60
100Day EMA
146.20
200Day EMA
134.10
5Day SMA
167.00
10Day SMA
167.30
20Day SMA
162.20
30Day SMA
165.40
50Day SMA
159.90
100Day SMA
143.30
150Day SMA
130.80
200Day SMA
124.70
Delivery & Volume

Delivery & Volume

PeriodCombined Delivery VolumeNSE+BSE Traded Volume
Day Rs
184755 Rs
436902 Rs
Week Rs
433567 Rs
1166916 Rs
Month Rs
539495 Rs
1661094 Rs
Resistance & Support
163.91
Pivot
Resistance
First Resistance
165.83
Second Resistance
168.58
Third Resistance
170.50
Support
First Support
161.16
Second support
159.24
Third Support
156.49
Relative Strength Index
50.34
Money Flow Index
72.95
MACD
1.76
MACD Signal
1.63
Average True Range
9.76
Average Directional Index
20.48
Rate of Change (21)
-3.67
Rate of Change (125)
60.84

Camlin Fine Sciences Latest News

23 APR 2025 | Wednesday

Camlin Fine Sciences Ltd - 532834 - Shareholder Meeting / Postal Ballot-Scrutinizer"s Report

23 APR 2025 | Wednesday

Camlin Fine Sciences Ltd - 532834 - Shareholder Meeting / Postal Ballot-Outcome of Postal Ballot

08 APR 2025 | Tuesday

Camlin Fine Sciences Ltd - 532834 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

View More

Camlin Fine Sciences Company background

Founded in: 1993
Managing director: Ashish S Dandekar
Camlin Fine Sciences Limited was originally incorporated on November 30, 1993 as a Private Limited Company with the name of Camlicon Consultants Private Limited. On June 1, 2006, the Company name was changed from Camlicon Consultants Private Limited to Camlin Fine Chemicals Private Limited. As per the Scheme of Arrangement, the Fine Chemicals Division of Camlin Limited got demerged and transferred to the Company effective from July 01, 2006. On August 11, 2006, the Company status was converted into Public Limited Company and the name was changed to Camlin Fine Chemicals Limited. W.e.f. 27th August, 2011 name of the Company was changed from Camlin Fine Chemicals Limited to Camlin Fine Sciences Limited.The Company is one of the Indias leading manufacturers and exporters of Bulk Drugs, Fine Chemicals and Food Grade products. It manufactures active pharmaceutical ingredients (APIs), food antioxidants and sweeteners. They operate in two business divisions, namely Food Ingredients Division and Industrial products Division. The companys products have applications in processed foods, edible oils, paints, polymers, alternative fuels (biodiesel), rubber, health, and pharmaceuticals.The company has a strong research and development which is focused on bringing in continual improvements on process and products, backward integration and developing innovative products. The research and development is equipped with comprehensive and updated instrumentation for conducting quality analysis, stability studies. The research and development also is equipped to conduct application studies on stability index of edible oils and Biodiesel.In April 2006, the main object of the Company was altered to enable the Company to pursue business in Fine Chemicals. They launched a new product namely, Sucralose which is a synthetic sweetener with large demand and attractive price.The company entered into a joint venture with Viachem LLC USA on 51:49 basis and set up a company namely, Dulcette Technologies LLC for marketing Sucralose, Aspartame and AcesulfameK and their blends in USA, Canada and Mexico. In March 30, 2007, the equity shares of the company were listed on the Bombay Stock Exchange (BSE).During the year 200708, the company increased the production capacity of Chemical Chemical Products from 1,636 Ltrs/Kgs to 2,476 Ltrs/Kgs. The company acquired the control of Sangam Laboratories Ltd by acquiring 60% of the paid up equity share capital of the company. They invested Rs 5 lakh for controlling interest in the Equity Share Capital of Chemolutions Chemicals Ltd. In February 2008, the company entered into a joint venture agreement with Advanced Aerospace Technologies Inc., USA to manufacture and market speciality fine chemicals primarily to cater to European and U.S markets. During the year 200809, the company expanded the production capacity of Chemical Chemical Products from 2,476 Ltrs/Kgs to 2,548 Ltrs/Kgs. The company invested Rs 25.50 lakh in Fine Lifestyle Brands Ltd and Rs.5.10 lakh in Fine Renewable Energy Ltd, which represents 51% of equity share capital of each of them. They further invested Rs 92.32 lakh in the share capital of their present subsidiaries, namely Sangam Laboratories Ltd, Chemolutions Chemicals Ltd and Dulcette Technologies LLC, USA.During the year 200910, the company expanded the production capacity of Chemical Chemical Products from 2,458 Ltrs/Kgs to 3,500 Ltrs/Kgs. They are entering the field of Bio technology products and first patented, biotechnology based Natural shelf life enhancing formula for increasing shelf life of Natural farm produce, like fruits, vegetables and flowers.During the year 2011, Chemolutions Chemicals Limited, Fine Lifestyle Brands Limited and Fine Renewable Energy Limited ceased to be subsidiaries of the Company. The Honble High Court Bombay, vide order dated 21st April, 2011 approved Scheme of Amalgamation for merger of Sangam Laboratories Limited, a 100% owned subsidiary with the Company. The establishment of two major business divisions, namely, Food and Industrial Products was completed. The Company expanded its manufacturing capacity of the food antioxidants, Ascorbyl Palmitate, TBHQ and BHA in 201213. In January 2016, it started operations in Central America with the launch of CFS Antioxidantes De Mexico, S.A. de C.V., a 100% subsidiary of Camlin Fine Sciences Ltd., acquired 65% stake in Dresen Qumica S.A.P.I de C.V, a leading food and feed blend company in Mexico launched CFS North America, LLC, a 100% owned subsidiary of CFS for manufacturing and selling of customised antioxidant blends launched Evanil, ethyl vanillin for food and bakery industry.On 15th April, 2016, a 100% wholly owned subsidiary CFS International Trading (Shanghai) Ltd. was incorporated in China (Shanghai) pilot free trade zone to manufacture and deal in speciality chemicals. On 22nd March, 2017, Chemolutions Chemicals Limited (CCL) allotted 62,67,003 equity shares on preferential basis to the Company. Post allotment, the shareholding of Company in CCL was 94.08% and CCL became the subsidiary of the Company. In July 2017, Company through its wholly owned stepdown subsidiary viz. CFS Europe S.p.A. acquired 51% stake in CFS Wanglong Flavours (Ningbo) Co. Ltd. erstwhile Ningbo Wanglong Flavors and Fragrances Company Limited. In April 2018, Company signed a joint venture contract with Pahang Pharma (S) Pte. Ltd., Singapore (Pahang) for incorporating a holding company, shareholding in the proportion of 51:49, named CFS Pahang Asia Pte. Ltd. in Singapore.In 2019, the Company reverse merged its wholly owned subsidiary in Mauritius viz., CFCL Mauritius Private Limited into CFS Europe Spa, Italy effective 25th June, 2019 and resultant to this merger, CFS Europe Spa became a whollyowned subsidiary. The reverse merger of CFS Antioxidnates De Mexico De CV with Dresen Quimica SAPI De CV was effective 31st January, 2019 and resultant to reverse merger, CFS Antioxidantes De Mexico S.A. de. C.V. ceased to be the whollyowned subsidiary of the Company from the aforementioned date. As a part of this initiative, Company acquired a company situated in Southern part of India, namely, AlgalR Nutrapharms Private Limited (AlgalR) which manufactures oils containing Omega 3 Fatty Acids. The company embarked upon its largest greenfield expansion in 2018 in Dahej, Gujarat for a greentechnologybased DiPhenol plant for a 10,000 MT DiPhenol facility. And in September 2020, it announced the commercial production of Hydroquinone and Catechol.During the financial year 202122, AlgalR NutraPharms Private Limited and CFS De Mexico Blends SAPI De CV became subsidiaries and Fine Lifestyle Brands Limited has ceased to be a Associate of the Company.The Company initiated the commercial production of Vanillin and Ethyl Vanillin in Dahej in January, 2023 in FY 202324.
Read More

Camlin Fine Sciences FAQs

Camlin Fine Sciences share price is ₹162.15 in NSE and ₹162.05 in BSE as on 30/4/2025.

Camlin Fine Sciences share price in the past 1-year return was 53.22. The Camlin Fine Sciences share hit a 1-year low of Rs. 78.11 and a 1-year high of Rs. 180.86.

The market cap of Camlin Fine Sciences is Rs. 3064.43 Cr. as of 30/4/2025.

The PE ratios of Camlin Fine Sciences is 0 as of 30/4/2025.

The PB ratios of Camlin Fine Sciences is 3.58 as of 30/4/2025

The Mutual Fund Shareholding in Camlin Fine Sciences was 3.48% at the end of 30/4/2025.

You can easily buy Camlin Fine Sciences shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Please be aware that Camlin Fine Sciences stock prices are subject to continuous fluctuations due to various factors.

Open Demat Account
+91 -

personImage
Open Demat Account
+91 -